Phase 2 Trial of First-Line Therapy With Satraplatin and Paclitaxel in Patients With Unresectable Stage III or IV Non-small Cell Lung Cancer (NSCLC)
This trial is designed to study the efficacy and safety of a novel oral platinum analog,
satraplatin, in combination with another chemotherapy drug, paclitaxel, for the first line
of treatment (patients who have not received chemotherapy for disease that has metastasized)
of patients with advanced NSCLC.
WHAT IS SATRAPLATIN:
Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based
drugs have been clinically proven to be one of the most effective classes of anticancer
therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given
orally.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To examine overall response rates in patients with advanced NSCLC treated with a first-line regimen of satraplatin and paclitaxel
3 months
Yes
United States: Food and Drug Administration
SAT2-05-05
NCT00268970
December 2005
September 2009
Name | Location |
---|---|
Sarah Cannon Research Institute | Nashville, Tennessee 37203 |